Spinal Cord Injury (SCI) is a devastating event with sudden onset of motor and sensory dysfunction. Damage to autonomic neurons at and below the level of injury leads to bowel, bladder, and sexual functional loss.
The total prevalent population of Spinal Cord Injury in 7MM [i.e. the United States, EU5 (Spain, Germany, Italy, France, and the UK) and Japan] was 652,542 in 2017. The incidence of SCI in the United States was 17,589 while japan had an incidence of 5,058 in 2017.
As per DelveInsight, the therapeutic market of Spinal Cord Injury in the 7MM was found to be USD 1,282.04 million in 2017.
Some of the key factors expected to drive the Spinal Cord Injury market include an absence of therapies in the market, an increase in the affected population, and poor efficacy and side effects associated with current therapies.
Key companies operating in the Spinal Cord Injury market include StemCyte, Lineage Cell Therapeutics, Kringle Pharma, AbbVie, Nipro Corporation, ReNetX Bio, Neurofix, and many others.
For more detailed information, visit: Spinal Cord Injury Market Share